Edinburgh, Scotland-based start-up Trogenix has raised £70 million ($95 million) for a pipeline of therapies for hard-to-treat aggressive cancer, starting with glioblastoma. The University of Edinburgh spinout, set up in early 2024 by investment group 4BIO Capital, has the bold ambition of transforming cancer therapy from chronic disease management to potentially curative one-time treatments. Its…
Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Just a few months after emerging from the Flagship Pioneering incubator with $200 million in seed financing, Lila Sciences has raised another $235 million in a first round that will further the development of its AI-powered, fully autonomous lab technology. The Series A, co-led by Braidwell and Collective Global, will help Lila meet its goal…
WASHINGTON — Vinay Prasad is returning to the Food and Drug Administration to resume his role overseeing vaccine, gene therapy, and blood product regulation. “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,” Health and Human Services spokesperson Andrew Nixon told STAT on Saturday. STAT+ Exclusive…
